培训课件_β受体阻滞剂心衰治疗若干问题及STELLAR研究.pptVIP

EF ￡ 40% EF 40% not on an ACEI (N = 3022) ACEI intolerant (N = 2000) ACEI treated (N = 2548) Randomization Randomization Candesartan 4/8 32 mg Placebo Primary endpoint = CV death and CHF hospitalization Overall endpoint = all-cause mortality Randomization CHF: NYHA class II - IV Total N = 7500 Duration = 42 mo. (McMurray J, et al. Presented at ESC 2000) CHARM Trial Program CHARM - Altermative ARB vs placebo (bB+, bB-) 亚组分拆 bB+ ARB + bB vs bB bB - ARB vs placebo CHARM - added ARB + ACEI vs ACEI (bB+, bB-) 亚组分拆 bB+